The stock of Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH) reached all time low today, Nov, 4 and still has $2.91 target or 14.00% below today’s $3.38 share price. This indicates more downside for the $124.04M company. This technical setup was reported by Barchart.com. If the $2.91 PT is reached, the company will be worth $17.37 million less.
Trading stocks at an all time low is not easy. Stock at an all time low usually experience even more downside due to very negative fundament. Even thought the pullback rate is high, shorting is not an easy job because the risk of being wrong is big and the risk-reward ratio is always worse than if trading lon only. About 160,152 shares traded hands. Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH) has declined 32.29% since April 4, 2016 and is downtrending. It has underperformed by 33.38% the S&P500.
Analysts await Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH) to report earnings on November, 7. They expect $-0.49 EPS, 0.00% or $0.00 from last year’s $-0.49 per share. After $-0.47 actual EPS reported by Tetraphase Pharmaceuticals Inc for the previous quarter, Wall Street now forecasts 4.26% negative EPS growth.
Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH) Ratings Coverage
Out of 11 analysts covering Tetraphase Pharmaceuticals (NASDAQ:TTPH), 1 rate it a “Buy”, 0 “Sell”, while 10 “Hold”. This means 9% are positive. Tetraphase Pharmaceuticals has been the topic of 15 analyst reports since August 6, 2015 according to StockzIntelligence Inc. The rating was maintained by Brean Capital with “Buy” on Thursday, August 6. As per Wednesday, September 9, the company rating was downgraded by SunTrust. The stock of Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH) earned “Neutral” rating by Wedbush on Wednesday, September 9. The stock of Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH) has “Buy” rating given on Thursday, August 6 by Stifel Nicolaus. Brean Capital downgraded the stock to “Hold” rating in Wednesday, September 9 report. The rating was initiated by BMO Capital Markets with “Market Perform” on Tuesday, April 12. The firm has “Hold” rating by Needham given on Wednesday, September 9. The firm has “Hold” rating by Cantor Fitzgerald given on Wednesday, September 9. On Wednesday, September 9 the stock rating was downgraded by Robert W. Baird to “Neutral”. Gabelli downgraded the shares of TTPH in a report on Friday, May 13 to “Neutral” rating.
According to Zacks Investment Research, “Tetraphase Pharmaceuticals, Inc. is a life science company engaged in developing and commercializing tetracycline based drugs to treat drug-resistant infectious diseases, inflammation, and cancer. Its principal products include eravacycline, an intravenous and oral antibiotic for the treatment of multi-drug resistant Gram-negative infections. The Company’s product under development includes eravacycline oral formulation, TP-834 and TP-271. Tetraphase Pharmaceuticals, Inc. is based in Watertown, Massachusetts.”
Insitutional Activity: The institutional sentiment decreased to 0.86 in 2016 Q2. Its down 0.31, from 1.17 in 2016Q1. The ratio fall, as 18 funds sold all Tetraphase Pharmaceuticals Inc shares owned while 26 reduced positions. 14 funds bought stakes while 24 increased positions. They now own 21.31 million shares or 7.27% less from 22.99 million shares in 2016Q1.
Federated Investors Incorporated Pa holds 0% of its portfolio in Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH) for 93,303 shares. American Intll Group accumulated 20,926 shares or 0% of the stock. Gabelli Funds Limited Liability Company holds 0% or 120,000 shares in its portfolio. Rhenman And Asset Mgmt last reported 300,000 shares in the company. California Employees Retirement Systems last reported 0% of its portfolio in the stock. Dimensional Fund Advisors Limited Partnership accumulated 0% or 25,450 shares. Fmr Ltd Liability owns 1.97M shares or 0% of their US portfolio. Wells Fargo And Communication Mn last reported 14,402 shares in the company. Citigroup accumulated 9,824 shares or 0% of the stock. Moreover, Tiaa Cref Investment Limited Liability has 0% invested in Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH) for 230,758 shares. Vanguard Inc has 1.29M shares for 0% of their US portfolio. Sunbelt Secs last reported 0% of its portfolio in the stock. Putnam Invs Ltd holds 75,000 shares or 0% of its portfolio. Granahan Investment Mgmt Inc Ma has invested 0.11% of its portfolio in Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH). Morgan Stanley has 0% invested in the company for 24,279 shares.
More notable recent Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH) news were published by: Fool.com which released: “Why Tetraphase Pharmaceuticals Inc Stock Was Annihilated Today” on September 09, 2015, also Marketwatch.com with their article: “Tetraphase’s stock tumbles 21% to record low” published on April 15, 2013, Fool.com published: “Why Tetraphase Pharmaceuticals Dropped 74% of Its Value in 2015” on January 11, 2016. More interesting news about Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH) were released by: Globenewswire.com and their article: “Tetraphase Pharmaceuticals Reports Second Quarter 2016 Financial Results and …” published on August 04, 2016 as well as Quotes.Wsj.com‘s news article titled: “News Tetraphase Pharmaceuticals Inc.TTPH” with publication date: March 22, 2013.
TTPH Company Profile
Tetraphase Pharmaceuticals, Inc. (Tetraphase), incorporated on July 7, 2006, is a clinical-stage biopharmaceutical company. The Firm uses its chemistry technology to create antibiotics for multidrug-resistant infections. The Firm is developing its lead product candidate, eravacycline, a fully synthetic tetracycline derivative, as a spectrum intravenous (IV) and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multidrug-resistant infections, including multidrug-resistant Gram-negative infections. The Firm also develops TP-6076 for multidrug-resistant Gram- negative infections.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.